Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wak

Go back to Harmony Biosciences Reports Strong First Quarter Financial Results and Acceleration of Its Growth Strategy; Advances Pitolisant Franchise to Extend Revenue Potential Beyond 2040; Strenghtens Sleep/Wak
Harmony Metals, Inc. Common (NASDAQ: HRMY) Delayed: 36.13 +0.10 (0.28%)
Previous Close $36.03    52 Week High $1.35 
Open $36.11    52 Week Low $0.10 
Day High $37.05    P/E N/A 
Day Low $35.00    EPS $0.00 
Volume 2,313,566